These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18073583)

  • 1. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.
    Veenstra DL; Harris J; Gibson RL; Rosenfeld M; Burke W; Watts C
    Genet Med; 2007 Oct; 9(10):695-704. PubMed ID: 18073583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?
    Al-Malky G; Suri R; Sirimanna T; Dawson SJ
    Int J Pediatr Otorhinolaryngol; 2014 Jun; 78(6):969-73. PubMed ID: 24703164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides.
    Huang SP; McKinzie CJ; Tak CR
    J Manag Care Spec Pharm; 2021 Feb; 27(2):157-165. PubMed ID: 33506732
    [No Abstract]   [Full Text] [Related]  

  • 4. [Assessment of the risk of hearing loss in children with cystic fibrosis].
    Polyakov DP; Daikhes NA; Bazanova MV; Melyanovskaya YL
    Vestn Otorinolaringol; 2024; 89(3):29-35. PubMed ID: 39104270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Familial susceptibility to aminoglycoside ototoxicity due to the A1555G mutation in the mitochondrial DNA].
    Gallo-Terán J; Morales-Angulo C; del Castillo I; Moreno-Pelayo MA; Mazón A; Moreno F
    Med Clin (Barc); 2003 Jul; 121(6):216-8. PubMed ID: 12882732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.
    Handelsman JA; Nasr SZ; Pitts C; King WM
    Pediatr Pulmonol; 2017 Sep; 52(9):1157-1162. PubMed ID: 28737283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
    Lanvers-Kaminsky C; Ciarimboli G
    Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
    McRorie TI; Bosso J; Randolph L
    Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of the A1555G mutation in the mitochondrial DNA in patients with cochlear or vestibular damage due to aminoglycoside-induced ototoxicity].
    Gallo-Terán J; Arellano B; Morales-Angulo C; Modamio-Høybjør S; Moreno-Pelayo MA; Ramírez-Camacho R; del Castillo I; Moreno F
    Acta Otorrinolaringol Esp; 2004 May; 55(5):212-7. PubMed ID: 15461317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
    Geyer LB; Menna Barreto SS; Weigert LL; Teixeira AR
    Braz J Otorhinolaryngol; 2015; 81(6):589-97. PubMed ID: 26480907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of aminoglycoside-induced and prelingual non-syndromic mitochondrial hearing impairment: a review.
    Bindu LH; Reddy PP
    Int J Audiol; 2008 Nov; 47(11):702-7. PubMed ID: 19031229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.
    O'Donnell EP; Scarsi KK; Scheetz MH; Postelnick MJ; Cullina J; Jain M
    Int J Antimicrob Agents; 2010 Jul; 36(1):94-5. PubMed ID: 20382508
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic susceptibility to aminoglycoside ototoxicity.
    Nguyen T; Jeyakumar A
    Int J Pediatr Otorhinolaryngol; 2019 May; 120():15-19. PubMed ID: 30743189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside induced ototoxicity risk in the cystic fibrosis population: The utility of large-scale screening.
    Lopes J; Vidal-Folch N; Lundquist P; Schimmenti LA; Demirel N; Dean V; Olson J; Auth T; Butz M; Reed K; Wylam M; Balcom J; Boczek NJ; Hasadsri L
    Pediatr Pulmonol; 2023 Mar; 58(3):819-824. PubMed ID: 36437230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
    Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
    Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is deafness mutation screening required in cystic fibrosis patients?
    Abusamra R; McShane D
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():24-6. PubMed ID: 27427311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation and mitochondrial DNA sequence analysis in two Chinese families with aminoglycoside-induced and non-syndromic hearing loss.
    Zhao L; Wang Q; Qian Y; Li R; Cao J; Hart LC; Zhai S; Han D; Young WY; Guan MX
    Biochem Biophys Res Commun; 2005 Oct; 336(3):967-73. PubMed ID: 16168391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.